Please try another search
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Craig Eagle | 56 | 2021 | Independent Director |
Christopher C. Chapman | 70 | 2020 | President, Chief Medical Officer & Director |
Joshua N. Silverman | 53 | 2018 | Independent Chairman of the Board |
Jeremy D. Walston | - | - | Member of Scientific Advisory Board |
Billy Joe White | 62 | 2017 | Independent Director |
Jude C. Uzonwanne | 49 | 2021 | Independent Director |
Christopher C. Schreiber | 58 | 2017 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review